儿童出院后恶心和呕吐(PDNV):回顾和观察性研究。

IF 0.7 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Biomedical Papers-Olomouc Pub Date : 2023-06-01 DOI:10.5507/bp.2023.020
Michal Frelich, Vojtech Vodicka, Ondrej Jor, Filip Bursa, Martin Formanek, Peter Sklienka, Vaclav Prochazka
{"title":"儿童出院后恶心和呕吐(PDNV):回顾和观察性研究。","authors":"Michal Frelich,&nbsp;Vojtech Vodicka,&nbsp;Ondrej Jor,&nbsp;Filip Bursa,&nbsp;Martin Formanek,&nbsp;Peter Sklienka,&nbsp;Vaclav Prochazka","doi":"10.5507/bp.2023.020","DOIUrl":null,"url":null,"abstract":"<p><p>Postdischarge nausea and vomiting (PDNV) cause substantial pediatric morbidity with potentially serious postoperative complications. However, few studies have addressed PDNV prevention and treatment in pediatric patients. Here we searched the literature and processed it in a narrative review describing PDNV incidence, risk factors, and management in pediatric patients.. A successful strategy for reducing PDNV considers both the pharmacokinetics of the antiemetic agents and the principle of multimodal prophylaxis, utilizing agents of different pharmacologic classes. Since many highly effective antiemetic agents have relatively short half-lives, a different approach must be used to prevent PDNV. A combination of oral and intravenous medications with longer half-lives, such as palonosetron or aprepitant, can be used. In addition, we designed a prospective observational study with the primary objective of determining PDNV incidence. In our study group of 205 children, the overall PDNV incidence was 14.6% (30 of 205), including 21 children suffering from nausea and 9 suffering from vomiting.</p>","PeriodicalId":55363,"journal":{"name":"Biomedical Papers-Olomouc","volume":"167 2","pages":"109-115"},"PeriodicalIF":0.7000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Postdischarge nausea and vomiting (PDNV) in children: A review and observational study.\",\"authors\":\"Michal Frelich,&nbsp;Vojtech Vodicka,&nbsp;Ondrej Jor,&nbsp;Filip Bursa,&nbsp;Martin Formanek,&nbsp;Peter Sklienka,&nbsp;Vaclav Prochazka\",\"doi\":\"10.5507/bp.2023.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Postdischarge nausea and vomiting (PDNV) cause substantial pediatric morbidity with potentially serious postoperative complications. However, few studies have addressed PDNV prevention and treatment in pediatric patients. Here we searched the literature and processed it in a narrative review describing PDNV incidence, risk factors, and management in pediatric patients.. A successful strategy for reducing PDNV considers both the pharmacokinetics of the antiemetic agents and the principle of multimodal prophylaxis, utilizing agents of different pharmacologic classes. Since many highly effective antiemetic agents have relatively short half-lives, a different approach must be used to prevent PDNV. A combination of oral and intravenous medications with longer half-lives, such as palonosetron or aprepitant, can be used. In addition, we designed a prospective observational study with the primary objective of determining PDNV incidence. In our study group of 205 children, the overall PDNV incidence was 14.6% (30 of 205), including 21 children suffering from nausea and 9 suffering from vomiting.</p>\",\"PeriodicalId\":55363,\"journal\":{\"name\":\"Biomedical Papers-Olomouc\",\"volume\":\"167 2\",\"pages\":\"109-115\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical Papers-Olomouc\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5507/bp.2023.020\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Papers-Olomouc","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5507/bp.2023.020","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

出院后恶心和呕吐(PDNV)引起大量儿科发病率和潜在的严重术后并发症。然而,很少有研究涉及PDNV在儿科患者的预防和治疗。在这里,我们检索了文献,并对其进行了叙述性回顾,描述了PDNV在儿科患者中的发病率、危险因素和管理。减少PDNV的成功策略既考虑止吐剂的药代动力学,又考虑多模式预防原则,利用不同药理学类别的药物。由于许多高效止吐剂的半衰期相对较短,因此必须采用不同的方法来预防PDNV。可以联合使用半衰期较长的口服和静脉注射药物,如帕洛诺司琼或阿瑞吡坦。此外,我们设计了一项前瞻性观察研究,主要目的是确定PDNV的发病率。本研究组205例患儿中,PDNV总发病率为14.6%(30 / 205),其中21例患儿出现恶心,9例患儿出现呕吐。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Postdischarge nausea and vomiting (PDNV) in children: A review and observational study.

Postdischarge nausea and vomiting (PDNV) cause substantial pediatric morbidity with potentially serious postoperative complications. However, few studies have addressed PDNV prevention and treatment in pediatric patients. Here we searched the literature and processed it in a narrative review describing PDNV incidence, risk factors, and management in pediatric patients.. A successful strategy for reducing PDNV considers both the pharmacokinetics of the antiemetic agents and the principle of multimodal prophylaxis, utilizing agents of different pharmacologic classes. Since many highly effective antiemetic agents have relatively short half-lives, a different approach must be used to prevent PDNV. A combination of oral and intravenous medications with longer half-lives, such as palonosetron or aprepitant, can be used. In addition, we designed a prospective observational study with the primary objective of determining PDNV incidence. In our study group of 205 children, the overall PDNV incidence was 14.6% (30 of 205), including 21 children suffering from nausea and 9 suffering from vomiting.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biomedical Papers-Olomouc
Biomedical Papers-Olomouc MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
2.30
自引率
0.00%
发文量
74
审稿时长
6-12 weeks
期刊介绍: Biomedical Papers is a journal of Palacký University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Czech Republic. It includes reviews and original articles reporting on basic and clinical research in medicine. Biomedical Papers is published as one volume per year in four issues.
期刊最新文献
FOXP3, IL-35, and PD-L1 in intra- and peritumoral lymphocytic infiltrate of cutaneous melanomas as an important part of antitumor immunity. Unveiling the predictive power of biomarkers in traumatic brain injury: A narrative review focused on clinical outcomes. Uterine artery embolisation in symptomatic patients with placenta accreta spectrum disorders. Induction of supraventricular tachycardias in patients undergoing pulmonary vein isolation for paroxysmal atrial fibrillation is safe and reasonable. Association of biomarkers of cardiac remodeling, myocardial fibrosis and inflammation with parameters of heart function and structure in patients with arterial hypertension.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1